摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(E)-ethyl 5,5-dimethylhex-2-enoate | 34993-65-2

中文名称
——
中文别名
——
英文名称
(E)-ethyl 5,5-dimethylhex-2-enoate
英文别名
ethyl 5,5-dimethyl-2-hexenoate;ethyl 5,5-dimethylhex-2-enoate;ethyl (E)-5,5-dimethylhex-2-enoate
(E)-ethyl 5,5-dimethylhex-2-enoate化学式
CAS
34993-65-2
化学式
C10H18O2
mdl
——
分子量
170.252
InChiKey
MUMIFLHCHVRJEF-VOTSOKGWSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    60 °C(Press: 0.05 Torr)
  • 密度:
    0.892±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    12
  • 可旋转键数:
    5
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.7
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    2

SDS

SDS:de1d417b08d8adc87d2937afe8ad833b
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Excitatory amino-acid receptor agonists. Synthesis and pharmacology of analogues of 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid
    摘要:
    We have previously proposed the existence of a lipophilic cavity of the 2-amino-3-(3-hydroxy-5-methylisoxazol4-yl)propionic acid (AMPA) receptor recognition site capable of accommodating alkyl substituents of limited size in the 5-position of the isoxazole ring. In order to indirectly elucidate the approximate extent of this proposed cavity we have synthesized and pharmacologically characterized a number of AMPA analogues. For most of these AMPA analogues, a positive correlation between AMPA receptor affinity and agonist effect was observed. The only exception was demethyl-AMPA (8a), which showed relatively high AMPA receptor affinity (IC50 = 0.27 mu M) but remarkably weak agonist potency (EC50 = 900 mu M). Whereas the ethyl analogue of AMPA (Et-AMPA) (IC50 = 0.030 mu M; EC50 = 2.3 mu M) has previously been shown to be slightly more potent than AMPA (IC50 = 0.040 mu M; EC50 = 3.5 mu M), substitutions of a propyl or a butyl group for the methyl group of AMPA to give 8b (IC50 = 0.090 mu M; EC50 = 5.0 mu M) or 8f (IC50 = 1.0 mu M; EC50 = 32 mu M), respectively, result in progressive loss of the AMPA agonist effect. Analogues containing larger groups, such as isopentyl (8e), 1-propylbutyl (8g), 2,2-dimethylpropyl (8h), or benzyl (14) groups, were very weak or totally inactive as AMPA receptor ligands.
    DOI:
    10.1016/s0223-5234(97)89085-x
  • 作为产物:
    描述:
    参考文献:
    名称:
    N-酰基-5,5-二甲基恶唑烷-2-酮作为潜在的醛当量。
    摘要:
    对5,5-二甲基恶唑烷丁-2-酮,4,4-二甲基恶唑烷丁-2-酮和恶唑烷丁-2-酮的N-氢肉桂酰基衍生物进行DIBAL-H氢化还原后的性质研究表明,5,5 -二甲基基团对于抑制内环亲核攻击是必不可少的。例如,用DIBAL-H处理N-氢肉桂酰基-5,5-二甲基恶唑烷丁-2-酮可选择性地形成稳定的N-1'-羟烷基衍生物,该衍生物可被视为掩蔽的氢肉桂醛当量,如在碱性条件下,母体醛的产率高。在相同条件下用DIBAL-H处理N-氢肉桂酰基-4,4-二甲基恶唑烷-2-酮可提供复杂的产物混合物,包括内环裂解的甲酸酯产物。作为替代策略,用DIBAL-H还原直链和支链N-酰基-5,5-二甲基恶唑烷-2-酮衍生物,然后进行Horner-Wadsworth-Emmons反应,得到高产率的α,β-不饱和酯。N-酰基-恶唑烷酮中的α-到环外羰基分支可抑制DIBAL-H还原,但这可以通过与ZnCl2预络合来克服,随后
    DOI:
    10.1039/b301119d
点击查看最新优质反应信息

文献信息

  • “<i>Syn-Effect</i>” in the Conversion of (<i>E</i>)-α,β-Unsaturated Esters to the Corresponding β,γ-Unsaturated Esters
    作者:Samar Kumar Guha、Atsushi Shibayama、Daisuke Abe、Yutaka Ukaji、Katsuhiko Inomata
    DOI:10.1246/cl.2003.778
    日期:2003.8
    The stereochemistry in the conversion of (E)-α,β-unsaturated esters to the corresponding β,γ-unsaturated esters by treatment with lithium hexamethyldisilazide in the presence of HMPA was investigated. The Z/E ratios of the resulting β,γ-unsaturated esters varied according to the γ-substituents of the (E)-α,β-unsaturated esters. This phenomenon was rationalized by “syn-effect” which may be attributed
    研究了在 HMPA 存在下用六甲基二硅叠氮化锂处理将 (E)-α,β-不饱和酯转化为相应的 β,γ-不饱和酯的立体化学。所得β,γ-不饱和酯的Z/E比率根据(E)-α,β-不饱和酯的γ-取代基而变化。这种现象被“合成效应”合理化,这可能主要归因于 σ→π* 相互作用和/或 6π-电子同芳香性。
  • “<i>Syn-Effect</i>” in the Conversion of (<i>E</i>)-α,β-Unsaturated Esters into the Corresponding β,γ-Unsaturated Esters and Aldehydes into Silyl Enol Ethers
    作者:Samar Kumar Guha、Atsushi Shibayama、Daisuke Abe、Maki Sakaguchi、Yutaka Ukaji、Katsuhiko Inomata
    DOI:10.1246/bcsj.77.2147
    日期:2004.12
    The stereochemistry in the conversion of (E)-α,β-unsaturated esters into the corresponding β,γ-unsaturated esters, and that in the conversion of aldehydes into the silyl enol ethers, were investigated. The Z/E ratios of the resulting β,γ-unsaturated esters and the silyl enol ethers varied according to the γ-substituents of the (E)-α,β-unsaturated esters and the α-substituents of the aldehydes, respectively
    研究了(E)-α,β-不饱和酯转化为相应的β,γ-不饱和酯以及醛转化为甲硅烷基烯醇醚的立体化学。所得β,γ-不饱和酯和甲硅烷基烯醇醚的Z/E比率分别根据(E)-α,β-不饱和酯的γ-取代基和醛的α-取代基而变化。这种现象被“syn-effect”合理化,这可能主要归因于 σ → π* 相互作用和/或 6π-电子同芳香性。
  • Inhibitors of Histone Deacetylase
    申请人:Moradei Oscar
    公开号:US20080132459A1
    公开(公告)日:2008-06-05
    The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
    本发明涉及抑制组蛋白去乙酰化酶的方法。本发明提供了抑制组蛋白去乙酰化酶酶活性的化合物和方法。本发明还提供了用于治疗细胞增殖性疾病和病状的组合物和方法。
  • Microbiocidally active benzoxaboroles
    申请人:Syngenta Participations AG
    公开号:US10040806B2
    公开(公告)日:2018-08-07
    Compounds of formula (I) are as defined in the claims, and their use in compositions and methods for the control and/or prevention of microbial infection, particularly fungal infection, in plants and to processes for the preparation of these compounds.
    式(I)化合物如权利要求书中所定义,它们在控制和/或预防植物微生物感染,特别是真菌感染的组合物和方法中的用途,以及这些化合物的制备工艺。
  • Penicinotam derivative, preparation method and use thereof
    申请人:OCEAN UNIVERSITY OF CHINA
    公开号:US11040028B2
    公开(公告)日:2021-06-22
    Provided are penicinotam derivatives, a tautomer, a stereoisomer, a racemate, a nonequal mixture of enantiomers, a geometric isomer, a solvate, a pharmaceutically acceptable salt or a prodrug thereof, and a pharmaceutical composition comprising the derivatives. Also provided herein is use of the derivatives and the pharmaceutical compositions in treating diseases caused by inflammation, immune system disorders.
    本文提供了青霉胺衍生物、同分异构体、立体异构体、外消旋体、对映体的非等价混合物、几何异构体、溶液、其药学上可接受的盐或原药,以及包含这些衍生物的药物组合物。本文还提供了这些衍生物和药物组合物在治疗炎症引起的疾病、免疫系统疾病中的用途。
查看更多